What is Dynavax Technologies Book Value per Share?
Dynavax Technologies's book value per share for the quarter that ended in Dec. 2024 was $4.76.
During the past 12 months, Dynavax Technologies's average Book Value Per Share Growth Rate was -1.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 38.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 115.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 1.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Dynavax Technologies was 258.30% per year. The lowest was -65.00% per year. And the median was -8.20% per year.
During the past 13 years, the highest P/B Ratio of Dynavax Technologies was 67.41. The lowest was 1.41. And the median was 5.42.
Dynavax Technologies Book Value per Share Historical Data
The historical data trend for Dynavax Technologies's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Dynavax Technologies's Book Value per Share
For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dynavax Technologies's PB Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's PB Ratio distribution charts can be found below:
* The bar in red indicates where Dynavax Technologies's PB Ratio falls into.
Dynavax Technologies Book Value per Share Calculation
Dynavax Technologies's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Dynavax Technologies (NAS:DVAX) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Dynavax Technologies Book Value per Share Related Terms
Thank you for viewing the detailed overview of Dynavax Technologies's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DVAX has been successfully added to your 